Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control

International Journal of Radiation Oncology Biology Physics

Volumn 36, Issue 3, 1996, Pages 565-571

  Horwitz, Eric M ^a   Vicini, Frank A ^a   Ziaja, Ellen L ^a   Gonzalez, Jose ^a   Dmuchowski, Carl F ^a   Stromberg, Jannifer S ^a   Brabbins, Donald S ^a   Hollander, Jay ^a   Chen, Peter Y ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Biochemical control; Prostate cancer; Prostate specific antigen; Radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 0030271697     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00360-4     Document Type: Article

References (40)

1. 1. American Joint Committee on Cancer Prostate. In: Bearhrs, O. H.; Henson, D. R.; Hutter, R. V. P.; Kennedy, B. J., eds. Manual for staging of cancer, 4th ed. Philadelphia: J.B. Lippincott; 1992:181-186.
2. 2. Brawer, M. K.; Lange, P. H. Prostate specific antigen: Its role in early detection, staging, and monitoring of prostatic carcinoma. J. Endourol. 3:227-236; 1989.
3. 3. Catalona, W. J.; Smith, D. S.; Ratcliff, T. L.; Dodds, K. M.; Coplen, D. E.; Yuan, J. J.; Petros, J. A.; Andriole, G. L. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324:1156-1161; 1991.
4. 4. Chauvet, B.; Felix-Faure, C.; Lupsascka, N.; Fijuth, J.; Brewer, Y.; Davin, J.-L.; Kirscher, S.; Reboul, F. Prostate specific antigen decline: A major prognostic factor for prostate cancer treated with radiation therapy. J. Clin. Oncol. 12:1402-1407; 1994.
5. 5. Cox, J. D.; Kline, R. W. Do prostatic biopsies 12 months or more after external irradiation for adenocarcinoma Stage III predict long-term survival? Int. J. Radiat. Oncol. Biol. Phys. 9:299-303; 1983.
6. 6. Crook, J.; Robertson, S.; Collin, G.; Zaleski, V.; Esche, B. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate specific antigen following external beam radiotherapy for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 27:31-37; 1993.
7. 7. Dugan, T. C.; Shipley, W. U.; Young, R. H.; Verhey, L. J.; Althausen, A. F.; Heney, N. M.; McManus, P. L.; Abraham, E. H. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: Correlation with original histological grade and current prostate specific antigen levels. J. Urol. 146:1313-1316; 1991.
8. 8. Fijuth, J.; Chauvet, B.; Vincent, P.; Felix-Faure, C.; Reboul, F. Serum prostate specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy. Radiother. Oncol. 23:236-240; 1992.
9. 9. Frazier, H. A.; Robertson, J. E.; Humphrey, P. A.; Paulson, D. F. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J. Urol. 149:516-518; 1993.
10. 10. Goad, J. R.; Chang, S.-J.; Ohori, M.; Scardino, P. T. PSA after definitive radiotherapy for clinically localized prostate cancer. Urol. Clin. N. Am. 20:727-736; 1993.
11. 11. Hanks, G. E.; D'Amico, A.; Epstein, B. E.; Schulteiss, T. E. Prostatic specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int. J. Radiat. Oncol. Biol. Phys. 27:125-127; 1993.
12. 12. Kabalin, J. N.; Hodge, K. K.; McNeal, J. E.; Freiha, F. S.; Stamey, T. A. Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen. J. Urol. 142:326-331; 1989.
13. 13. Kaplan, E. L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481; 1958.
14. 14. Kaplan, I. D.; Cox, R. S.; Bagshaw, M. A. Prostate specific antigen after external beam radiotherapy for prostatic cancer: Follow-up. J. Urol. 149:519-522; 1993.
15. 15. Kavadi, V. S.; Zagars, G. K.; Pollack, A. Serum prostate specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int. J. Radiat. Oncol. Biol. Phys. 30:279-287; 1994.
16. 16. Kuban, D. A.; El-Mahdi, A. M.; Schellhammer, P. F. Prostate specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:307-316; 1995.
17. 17. Labrie, F.; Dupont, A.; Suburu, R.; Cusan, L.; Tremblay, M.; Gomez, J. L.; Emond, J. Serum prostate specific antigen as a prescreening test for prostate cancer. J. Urol. 147:846-851; 1992.
18. 18. Lange, P. H.; Ercole, C. J.; Lightner, D. J.; Fraley, E. E.; Vesella, R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 141:873-879; 1989.
19. 19. Lee, W. R.; Hanks, G. E.; Schultheiss, T. E.; Corn, B. W.; Hunt, M. A. Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis. J. Clin. Oncol. 13:464-469; 1995.
20. 20. Leibel, S. A.; Zelefsky, M. J.; Kutcher, G. J.; Burman, C. M.; Kelson, S.; Fuks, Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interim report of a phase 1 dose-escalation study. J. Urol. 152:1792-1798; 1994.
21. 21. Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22:719-748; 1959.
22. 22. McNemar, Q. Psychological studies. New York: Wiley; 1955.
23. 23. Morton, R. A.; Steiner, M. S.; Walsh, P. C. Cancer control following anatomical radical prostatectomy: An interim report. J. Urol. 145:1197-1200; 1991.
24. 24. Oesterling, J. E.; Chan, D. W.; Epstein, J. I.; Kimball, A. W.; Bruek, D. J.; Rock, R. C.; Brendler, C. B.; Walsh, P. C. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 139:766-772; 1988.
25. 25. Partin, A. W.; Pound, C. R.; Clemens, J. Q.; Epstein, J. I.; Walsh, P. C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Am. 20:713-725; 1993.
26. 26. Pisansky, T. M.; Cha, S. S.; Earle, J. D.; Durr, D. E.; Kozelsky, T. F.; Wieand, H. S.; Oesterling, J. E. Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 11:2158-2166; 1993.
27. 27. Ritter, M. A.; Messing, E. M.; Shanahan, T. G.; Potts, S.; Chappell, R. J.; Kinsella, T. J. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10:1208-1217; 1992.
28. 28. Russell, K. J.; Dunatov, C.; Hafermann, M. D.; Griffeth, J. T.; Polissar, L.; Pelton, J.; Cole, S. B.; Taylor, E. W.; Wiens, L. W.; Kesh, W. J.; Austin-Seymour, M. M.; Griffin, B. R.; Russell, A. H.; Laramore, G. E.; Griffin, T. W. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J. Urol. 146:1046-1052; 1991.
29. 29. Schellhammer, P. F.; El-Mahdi, A. M.; Wright, G. L.; Kolm, P.; Ragle, R. Prostate specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate. Urology 42:13-20; 1993.
30. 30. Stein, A.; DeKornion, J. B.; Smith, R. B.; Dorey, F.; Patel, H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J. Urol. 147:942-946; 1992.
31. 31. Zagars, G. K. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J. Urol. 152:1786-1791; 1994.
32. 32. Zagars, G. K. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy, Urol. Clin. N. Am. 20:737-747; 1993.
33. 33. Zagars, G. K. The prognostic significance of a single serum prostate specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 27:39-45; 1993.
34. 34. Zagars, G. K.; Pollack, A. Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urology 45:476-483; 1995.
35. 35. Zagars, G. K.; von Eschenbach, A. C. Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiation therapy. Cancer 72:538-548; 1993.
36. 36. Zagars, G. K.; Pollack, A.; Kavadi, V. S.; von Eschenbach, A. C. Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:293-306; 1995.
37. 37. Zeitman, A. L.; Coen, J. J.; Dallow, K. C.; Shipley, W. U. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome. Int. J. Radiat. Oncol. Biol. Phys. 32:287-292; 1995.
38. 38. Zeitman, A. L.; Coen, J. J.; Shipley, W. U.; Willett, C. G.; Efrid, J. T. Radical radiation therapy in the management of prostate adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J. Urol. 151:640-645; 1994.
39. 39. Zeitman, A. L.; Shipley, W. U.; Coen, J. J. Radical prostatectomy and radical radiation therapy for clinical stages T1 to T2 adenocarcinoma of the prostate: New insights into outcome from repeat biopsy and prostate specific antigen follow-up. J. Urol. 152:1806-1812; 1994.
40. 40. Zeitman, A. L.; Shipley, W. U.; Willett, C. G. Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer 71:959-969; 1993.